Literature DB >> 34629415

HIV Disease Dynamics and Markers of Inflammation and CNS Injury During Primary HIV Infection and Their Relationship to Cognitive Performance.

August A Longino1, Robert Paul2, Yixin Wang3, Javier R Lama4, Peter Brandes4, Eduardo Ruiz4, Cecilia Correa4, Sheila Keating5, Serena S Spudich6, Christopher Pilcher7, Alyssa Vecchio8, Siavash Pasalar3, Rachel A Bender Ignacio3,9, Rogelio Valdez10, Sayan Dasgupta3, Kevin Robertson8, Ann Duerr3,9.   

Abstract

INTRODUCTION: Early systemic and central nervous system viral replication and inflammation may affect brain integrity in people with HIV, leading to chronic cognitive symptoms not fully reversed by antiretroviral therapy (ART). This study examined associations between cognitive performance and markers of CNS injury associated with acute HIV infection and ART.
METHODS: HIV-infected MSM and transgender women (average age: 27 years and education: 13 years) enrolled within 100 days from the estimated date of detectable infection (EDDI). A cognitive performance (NP) protocol was administered at enrollment (before ART initiation) and every 24 weeks until week 192. An overall index of cognitive performance (NPZ) was created using local normative data. Blood (n = 87) and cerebrospinal fluid (CSF; n = 29) biomarkers of inflammation and neuronal injury were examined before ART initiation. Regression analyses assessed relationships between time since EDDI, pre-ART biomarkers, and NPZ.
RESULTS: Adjusting for multiple comparisons, shorter time since EDDI was associated with higher pre-ART VL and multiple biomarkers in plasma and CSF. NPZ scores were within the normative range at baseline (NPZ = 0.52) and at each follow-up visit, with a modest increase through week 192. Plasma or CSF biomarkers were not correlated with NP scores at baseline or after ART.
CONCLUSIONS: Biomarkers of CNS inflammation, immune activation, and neuronal injury peak early and then decline during acute HIV infection, confirming and extending results of other studies. Neither plasma nor CSF biomarkers during acute infection corresponded to NP scores before or after sustained ART in this cohort with few psychosocial risk factors for cognitive impairment.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34629415      PMCID: PMC8752485          DOI: 10.1097/QAI.0000000000002832

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  30 in total

1.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

2.  Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling.

Authors:  Ferdousi Chowdhury; Anthony Williams; Peter Johnson
Journal:  J Immunol Methods       Date:  2008-11-05       Impact factor: 2.303

3.  Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.

Authors:  Samanta Simioni; Matthias Cavassini; Jean-Marie Annoni; Aline Rimbault Abraham; Isabelle Bourquin; Véronique Schiffer; Alexandra Calmy; Jean-Philippe Chave; Ezio Giacobini; Bernard Hirschel; Renaud A Du Pasquier
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

4.  Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study.

Authors:  Ned Sacktor; Richard L Skolasky; Eric Seaberg; Cynthia Munro; James T Becker; Eileen Martin; Ann Ragin; Andrew Levine; Eric Miller
Journal:  Neurology       Date:  2015-12-30       Impact factor: 9.910

5.  Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Authors:  Serena Spudich; Magnus Gisslen; Lars Hagberg; Evelyn Lee; Teri Liegler; Bruce Brew; Dietmar Fuchs; Giuseppe Tambussi; Paola Cinque; Frederick M Hecht; Richard W Price
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

6.  International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.

Authors:  K Robertson; H Jiang; S R Evans; C M Marra; B Berzins; J Hakim; N Sacktor; M Tulius Silva; T B Campbell; A Nair; J Schouten; J Kumwenda; K Supparatpinyo; S Tripathy; N Kumarasamy; A la Rosa; S Montano; A Mwafongo; C Firnhaber; I Sanne; L Naini; F Amod; A Walawander
Journal:  J Neurovirol       Date:  2016-01-05       Impact factor: 2.643

7.  Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection.

Authors:  R A Stern; S G Silva; N Chaisson; D L Evans
Journal:  Arch Neurol       Date:  1996-02

8.  Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy.

Authors:  Idil Kore; Jintanat Ananworanich; Victor Valcour; James L K Fletcher; Thep Chalermchai; Robert Paul; Jesse Reynolds; Somporn Tipsuk; Sasiwimol Ubolyam; Somprartthana Rattanamanee; Linda Jagodzinski; Jerome Kim; Serena Spudich
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

9.  Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study.

Authors:  Marta Massanella; Rachel A Bender Ignacio; Javier R Lama; Amélie Pagliuzza; Sayan Dasgupta; Ricardo Alfaro; Jessica Rios; Carmela Ganoza; Delia Pinto-Santini; Trupti Gilada; Ann Duerr; Nicolas Chomont
Journal:  Lancet Microbe       Date:  2021-03-23

10.  Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV.

Authors:  Phillip Chan; Payal Patel; Joanna Hellmuth; Donn J Colby; Eugène Kroon; Carlo Sacdalan; Suteeraporn Pinyakorn; Linda Jagodzinski; Shelly Krebs; Jintanat Ananworanich; Victor Valcour; Serena Spudich
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

View more
  1 in total

1.  Immune Activation in Primary Human Immunodeficiency Virus: Influence of Duration of Infection, Treatment, and Substance Use.

Authors:  Trupti Gilada; Samuel R Schnittman; Edward White; Jacqueline Mercader; Yixin Wang; Sayan Dasgupta; Rogelio Valdez; Delia Pinto-Santini; Siavash Pasalar; Jorge Sanchez; Pedro Gonzales; Javier R Lama; Rachel Bender Ignacio; Ann Duerr
Journal:  Open Forum Infect Dis       Date:  2022-03-24       Impact factor: 4.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.